Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

MabSpace and Jiangsu Hengrui Collaborate on mAb Development

publication date: May 19, 2015
MabSpace Biosciences, an antibody discovery company, will co-develop novel antibody therapeutics on two targets with Jiangsu Hengrui Medicine. MabSpace will discover and select humanized lead antibodies using its proprietary immune tolerance breaking technology. Hengrui will be responsible for later development and own exclusive global rights to the candidates. MabSpace is headquartered in Hong Kong with an R&D lab in Suzhou's BioBay Park. More details....

Stock Symbol: (SHZ: 200513)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital